Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3712537 | 0.92 | MEN1 (0.46) | MAPTPOLBTP53KMT2AMEN1 | |
| SCHEMBL3701869 | 0.92 | IGF1R (0.41) | IGF1RMAPTEPHB4IRAK4POLB | |
| SCHEMBL3710717 | 0.87 | PTGER3 (0.41) | POLBKMT2AMEN1 | |
| SCHEMBL3702550 | 0.85 | PTGER3 (0.47) | MAPTKMT2AMEN1 | |
| SCHEMBL3704782 | 0.84 | ELANE (0.42) | MAPTKMT2AMEN1 | |
| SCHEMBL3702005 | 0.83 | PTGER3 (0.44) | MAPTEPHB4 | |
| SCHEMBL3708832 | 0.82 | IGF1R (0.50) | IGF1RMAPTEPHB4THRBIRAK4 | |
| Hydrochloric Acid SCHEMBL3700205 | 0.81 | IGF1R (0.49) | IGF1RMAPTEPHB4THRBIRAK4 | |
| SCHEMBL3708155 | 0.80 | P2RY1 (0.44) | — | |
| SCHEMBL3706703 | 0.78 | L3MBTL1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | IGF1R 41/4885MAPT 2492/4885EPHB4 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.